Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (NASDAQ: IPSC) reported significant progress in Q1 2025, highlighted by the initiation of patient dosing in the Phase 1 CALiPSO-1 trial for CNTY-101 in autoimmune disease. The company has expanded its clinical trial sites to Europe, with CTA authorizations in Germany, France, and Italy. The CARAMEL investigator-initiated trial is set to begin in mid-2025.
The company's lead preclinical program, CNTY-308, is scheduled to enter IND-enabling studies in mid-2025. At ASGCT's 28th Annual Meeting, Century showcased its preclinical pipeline featuring iPSC-derived 'tunable' CD4+/CD8+ ab T cells and Allo-Evasion™ 5.0 technology.
Financially, Century reported $185.8 million in cash and equivalents, expected to fund operations into Q4 2026. Q1 2025 saw $109.2 million in collaboration revenue following the termination of its Bristol-Myers Squibb agreement. The company posted a net income of $76.6 million, compared to a $28.1 million loss in Q1 2024.
Century Therapeutics (NASDAQ: IPSC), a leading biotech company focused on developing innovative cell therapies, has announced two significant presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting in New Orleans.
The presentations will showcase their groundbreaking work in:
- A poster session featuring research on iPSC-derived therapies with TGF-b neutralizing capabilities for enhanced solid tumor treatment
- An oral presentation demonstrating advances in iPSC-derived CD4+ and CD8+ CD19 CAR T cells showing promising tumor control capabilities
Key details of the event:
- Location: New Orleans Ernest N. Morial Convention Center
- Dates: May 13-17, 2025
- First presentation: May 13, 2025 (6:00-7:30 PM CDT)
- Second presentation: May 17, 2025 (11:15-11:30 AM CDT)
Presentation materials will be available in the Science section of Century's website after the event.
Century Therapeutics (NASDAQ: IPSC) has announced a live fireside chat scheduled for Tuesday, April 22, 2025, at 10:00 a.m. EDT to discuss their prioritized preclinical cell therapy programs. The event will showcase three key investigational therapies:
- CNTY-308: A CD19-targeted CAR-iT cell therapy
- CNTY-341: A CD19/CD22 dual-targeted CAR-iT cell therapy
- A solid tumor CAR iT program focusing on Nectin-4 CAR and other validated targets
All programs utilize advanced iPSC-derived 'tunable' CD4+/CD8+ ab T cells and incorporate the company's proprietary Allo-Evasion™ 5.0 technology, designed for comprehensive immune evasion. The presentation will also explore the potential expansion of their selective iPSC differentiation expertise to non-immune effector cells. The event will be accessible through Century's website, with a replay available for at least 30 days.
Century Therapeutics (NASDAQ: IPSC) announced a strategic pipeline re-prioritization focusing on four key programs, led by CNTY-308 for B-cell mediated autoimmune diseases. The company reported a strong financial position with $220.1M in cash as of December 31, 2024, extending runway into Q4 2026.
Key developments include:
- Early discontinuation of ELiPSE-1 trial in NHL
- First patient enrollment in CALiPSO-1 Phase 1 trial scheduled for March 2025
- CARAMEL investigator-initiated trial expected to commence mid-2025
- Expansion of CALiPSO-1 trial sites in US and Europe
Financial highlights for 2024:
- Net loss: $126.6M (improved from $136.7M in 2023)
- R&D expenses: $107.2M (up from $92.7M in 2023)
- G&A expenses: $33.2M (down from $34.7M in 2023)
- Collaboration revenue: $6.6M from Bristol-Myers Squibb partnership
Century Therapeutics (NASDAQ: IPSC) has announced a Phase 1/2 investigator-initiated trial (IIT) of its CD19 CAR-iNK cell therapy candidate CNTY-101 for B-cell mediated autoimmune diseases. The trial, known as CARAMEL, will be led by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg.
The study will evaluate CNTY-101's safety, efficacy, and translational data in patients with systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy, and diffuse cutaneous systemic sclerosis. This represents the first evaluation of an allogeneic iPSC-derived CD19-directed NK cell therapy for autoimmune diseases by the Schett/Mackensen group.
The CARAMEL trial is scheduled to begin in mid-2025 pending CTA approval. Additionally, Century plans to expand its ongoing Phase 1 CALiPSO-1 trial to include European sites.
Century Therapeutics (NASDAQ: IPSC), a biotech company focused on iPSC-derived cell therapies for immuno-oncology and autoimmune disease, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024. The company will be represented in two events: an Autoimmune Disease Cell Therapy Panel at 3:00 PM ET featuring CSO Chad Cowan, and a Fireside Chat at 4:30 PM ET with CEO Brent Pfeiffenberger and CSO Chad Cowan. A live webcast of the fireside chat will be available on the company's website with a 90-day replay option.
Century Therapeutics (NASDAQ: IPSC) reported Q3 2024 financial results and business updates. Key highlights include an 83% overall response rate for CNTY-101 at Dose Level 3B in B-cell lymphomas, and expansion of the Phase 1 CALiPSO-1 trial to include new autoimmune indications. The company ended Q3 with $244.7 million in cash and investments, extending runway into H2 2026. Q3 net loss was $31.2 million, with R&D expenses at $27.2 million. The company expects full-year GAAP operating expenses between $150-160 million. Following organizational restructuring, Century plans to announce results of its pre-clinical pipeline strategic review in Q1 2025.
Century Therapeutics (NASDAQ: IPSC) announced it will present preclinical data from its iPSC-derived cell therapy platform in five posters at the 2024 ASH Annual Meeting. The presentations will showcase advances in their iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune diseases. Key highlights include the development of iPSC-derived CD4+ and CD8+ CAR T cells with functionality comparable to primary αβ CAR-T cells, enhanced Allo-Evasion™ technology, and data demonstrating CAR iNK and γδ iT cells' potential in treating B-cell-mediated autoimmune diseases. The meeting will be held in San Diego from December 7-10, 2024.
Century Therapeutics (NASDAQ: IPSC), a biotech company focused on developing iPSC-derived cell therapies for immuno-oncology and autoimmune disease, has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. CEO Brent Pfeiffenberger and CSO Chad Cowan will engage in a fireside chat on November 12, 2024, at 9:30am ET. The presentation will be accessible via live webcast on the company's investor relations website, with replay available for 90 days post-event.
Century Therapeutics (NASDAQ: IPSC) has announced key leadership changes, effective October 2024. Morgan Conn, Ph.D., has been appointed as Chief Financial Officer, bringing over 20 years of financing and business development experience in biopharma. Chad Cowan, Ph.D., a cell therapy pioneer and founder of Clade Therapeutics, will serve as Chief Scientific Officer. Both will join the Executive Committee.
The company also announced that Hy Levitsky, M.D., President of Research and Development, will transition to an advisory role. These appointments come at a important time as Century advances its clinical programs, expands into autoimmune indications, and accelerates prioritized next-generation pipeline programs.
Century Therapeutics specializes in developing induced pluripotent stem cell (iPSC)-derived cell therapies for immuno-oncology and autoimmune diseases. The company's focus includes iNK, γδ iT, and αβ iT-cell programs, combined with its Allo-Evasion™ technology.